Product Images Rosuvastatin Calcium

This text appears to be a statistical result related to the comparison between two groups, one treated with Rosuva and the other with a placebo. The HR (Hazard Ratio) value is 0.56 with a 95% confidence interval ranging from 0.46 to 0.69. The reported p-value is less than 0.001. It also mentions the cumulative incidence in percentage, but the actual values are not readable. Additionally, there seems to be a table showing the number at risk in each group, but the numbers are partially readable. Therefore, a comprehensive description or interpretation of the results cannot be provided.*

The text provides information on the number of events and hazard ratios for different endpoints in a study comparing the effects of Rosuva 20 mg and Placebo 20 mg. The primary end point (MCE) had a hazard ratio of 0.56 (95% confidence interval: 0.46, 0.69), indicating a significant difference between the two groups (p<0.001). Other endpoints such as cardiovascular death, nonfatal stroke, nonfatal MI, hospitalized unstable angina, and arterial revascularization also showed significant differences between the two groups. The text also mentions that cardiovascular death included fatal MI, fatal stroke, sudden death, and other adjudicated causes of CV death.*